# US 2016/0355494 A1 · Fused heterocyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355494 A1
- Document ID: US20160355494A1
- Status: Published application
- Kind: A1
- Application number: 15/117,538
- Filed: 2015-02-12
- Published: 2016-12-08
- Earliest claimed: 2014-02-13
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Minoru SASAKI; Keiko KAKEGAWA; Fumiaki KIKUCHI; Zenichi IKEDA; Yoichi NISHIKAWA
- Web page: https://patentgrep.com/patent/US20160355494A1

## CPC

- C07D 307/81: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

## Claims

### Claim 1

A compound represented by the formula (I):
wherein
ring A represents a benzene ring optionally substituted by 1 to 3 substituents selected from a halogen atom, an optionally substituted C1-6 alkyl group, and an optionally substituted C1-6 alkoxy group;
R1 represents a hydrogen atom or a C1-6 alkyl group substituted by COOH; and
R2 represents a C1-6 alkyl group substituted by one or two COOH and further optionally substituted by SO3H,
or a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein ring A represents a benzene ring optionally substituted by 1 to 3 substituents selected from a halogen atom and a C1-6 alkyl group.

### Claim 3 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R1 represents a hydrogen atom or a C1-6 alkyl group substituted by one COOH.

### Claim 4 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R2 represents a C1-6 alkyl group substituted by one or two COOH.

### Claim 5 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein ring A represents a benzene ring optionally substituted by 1 to 3 substituents selected from a halogen atom and a C1-6 alkyl group, R1 represents a hydrogen atom or a C1-6 alkyl group substituted by one COOH, and R2 represents a C1-6 alkyl group substituted by one or two COOH.

### Claim 6

N-(((3S)-6-((4-Carbamimidamidobenzoyl)oxy)-2,3-dihydro-1-benzofuran-3-yl)acetyl)-L-aspartic acid or a salt thereof.

### Claim 7

N-(((3R)-6-((4-Carbamimidamidobenzoyl)oxy)-2,3-dihydro-1-benzofuran-3-yl)acetyl)-L-aspartic acid or a salt thereof.

### Claim 8

N-((6-((4-Carbamimidamidobenzoyl)oxy)-4-methyl-2,3-dihydro-1-benzofuran-3-yl)acetyl)-L-aspartic acid or a salt thereof.

### Claim 9 (depends on 1)

A medicament comprising the compound of claim 1 or a salt thereof.

### Claim 10 (depends on 9)

The medicament of claim 9, which is an enteropeptidase inhibitor.

### Claim 11 (depends on 9)

The medicament of claim 9, which is an agent for the prophylaxis or treatment of obesity.

### Claim 12 (depends on 9)

The medicament of claim 9, which is an agent for the prophylaxis or treatment of diabetes mellitus.

### Claim 13 (depends on 1)

A method for preventing or treating obesity in a mammal, comprising administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

### Claim 14 (depends on 1)

A method for preventing or treating diabetes mellitus in a mammal, comprising administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

### Claim 15 (depends on 1)

A method for inhibiting an enteropeptidase in a mammal, comprising administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

### Claim 16 (depends on 1)

Use of the compound according to claim 1 or a salt thereof in the production of an agent for the prophylaxis or treatment of obesity.

### Claim 17 (depends on 1)

Use of the compound according to claim 1 or a salt thereof in the production of an agent for the prophylaxis or treatment of diabetes mellitus.

### Claim 18 (depends on 1)

The compound according to claim 1 or a salt thereof for use in the prophylaxis or treatment of obesity.

### Claim 19 (depends on 1)

The compound according to claim 1 or a salt thereof for use in the prophylaxis or treatment of diabetes mellitus.
